Brand name: Rabeprazole Sodium (DRLA)
Rabeprazole Sodium (DRLA) is a medicine containing the active ingredient(s) rabeprazole. On this page you will find out more about Rabeprazole Sodium (DRLA), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: rabeprazole
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Rabeprazole Sodium (DRLA) 10 mg enteric tablet, 30
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
? Treatment and prevention of relapse of gastro-oesophageal reflux disease,? Symptomatic treatment of gastro-oesophageal reflux disease,? Treatment of duodenal ulcers,? Treatment of gastric ulcers.,Patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (NSAIDs) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,It is also indicated, in combination with clarithromycin and amoxycillin, for,? Eradication of Helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? Healing of peptic ulcers in patients with Helicobacter pylori associated ulcers.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance | Pink, round, biconvex coated tablets and plain on both sides. |
| Dosage Form | Tablet, enteric coated |
| Route of administration | Oral |
| Medicine schedule |
2,7,10,28,30 tablets: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | Do not Refrigerate,Do not Freeze |
| Life time | 24 Months |
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
